A Phase 2, Open Label Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K Dual δ/γ Inhibitor, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Unknown Phase 2 NCT04204057
Study Description
The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy and safety of Tenalisib in patients with CLL who have relapsed or are refractory after at least one prior therapy.
Study Details
- Registry ID:
- NCT04204057
- Conditions:
- Leukemia, Lymphocytic, Chronic, B-Cell
- Phase:
- Phase 2
- Target Enrollment:
- 21 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (6 sites)
-
University Multiprofile Hospital for Active Treatment "Sv Ivan Rilski" Ltd
Sofia, Bulgaria -
University Multiprofile Hospital for Active Treatment "Dr Georgi Stranski" Ltd.,
Pleven, Bulgaria -
Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J.
Chorzow, Poland -
Voivodship Multi-Specialist Center for Oncology and Traumatology M. Copernicus
Łódź, Poland -
Ltd. M.Zodelava Hematology Centre
Tbilisi, Georgia -
Medivest - Institute of Hematology and Transfusiology
Tbilisi, Georgia
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.